MEDICINOVA INC (MNOV) Stock Price & Overview
NASDAQ:MNOV • US58468P2065
Current stock price
The current stock price of MNOV is 1.45 USD. Today MNOV is up by 0.69%. In the past month the price increased by 10.77%. In the past year, price increased by 16.13%.
MNOV Key Statistics
- Market Cap
- 71.369M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.24
- Dividend Yield
- N/A
MNOV Stock Performance
MNOV Stock Chart
MNOV Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to MNOV. When comparing the yearly performance of all stocks, MNOV turns out to be only a medium performer in the overall market: it outperformed 62.03% of all stocks.
MNOV Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MNOV. While MNOV has a great health rating, there are worries on its profitability.
MNOV Earnings
On March 10, 2026 MNOV reported an EPS of -0.05 and a revenue of 151.74K. The company beat EPS expectations (48.4% surprise).
MNOV Forecast & Estimates
10 analysts have analysed MNOV and the average price target is 9.18 USD. This implies a price increase of 533.1% is expected in the next year compared to the current price of 1.45.
For the next year, analysts expect an EPS growth of -36% and a revenue growth -16.67% for MNOV
MNOV Groups
Sector & Classification
MNOV Financial Highlights
Over the last trailing twelve months MNOV reported a non-GAAP Earnings per Share(EPS) of -0.24. The EPS decreased by -4.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.31% | ||
| ROE | -28.85% | ||
| Debt/Equity | 0 |
MNOV Ownership
MNOV Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.99 | 369.265B | ||
| AMGN | AMGEN INC | 15.09 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.8 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.56 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.4 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.24 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.81 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.42 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MNOV
Company Profile
MediciNova, Inc. is a biopharmaceutical company, which focuses on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus. The company is headquartered in La Jolla, California and currently employs 6 full-time employees. The company went IPO on 2006-12-01. The firm's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.
Company Info
IPO: 2006-12-01
MEDICINOVA INC
4275 Executive Square, Suite 300
La Jolla CALIFORNIA 92037 US
CEO: Yuichi Iwaki
Employees: 6
Phone: 18583731500
MEDICINOVA INC / MNOV FAQ
What does MEDICINOVA INC do?
MediciNova, Inc. is a biopharmaceutical company, which focuses on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus. The company is headquartered in La Jolla, California and currently employs 6 full-time employees. The company went IPO on 2006-12-01. The firm's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.
What is the stock price of MEDICINOVA INC today?
The current stock price of MNOV is 1.45 USD. The price increased by 0.69% in the last trading session.
Does MNOV stock pay dividends?
MNOV does not pay a dividend.
What is the ChartMill rating of MEDICINOVA INC stock?
MNOV has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about MEDICINOVA INC (MNOV) stock?
10 analysts have analysed MNOV and the average price target is 9.18 USD. This implies a price increase of 533.1% is expected in the next year compared to the current price of 1.45.
Is MEDICINOVA INC (MNOV) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MNOV.
What is the employee count for MNOV stock?
MEDICINOVA INC (MNOV) currently has 6 employees.